Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 18Terminated 7Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Gulf War Illness 1Breast Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Mifepristone × Clear all
NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

University of Chicago

Phase 2 Active not recruiting
29 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04254627 2025-02-19

E/M

Nova Southeastern University

Phase 1 Active not recruiting
20 enrolled

Gulf War Illness

Data powered by HemOnc (CC BY 4.0) Colophon ⚡